FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Insulin resistance is the putative key underlying mechanism linking adipose tissue (AT) dysfunction with liver inflammation and steatosis in metabolic syndrome (MetS). We have recently demonstrated that the selective farnesoid X receptor (FXR) agonist obeticholic acid (OCA) ameliorates insulin resistance and the metabolic profile with a marked reduction in the amount of visceral AT (VAT) in a high-fat diet (HFD)-induced rabbit model of MetS. These effects were mediated by the activation of FXR, since treatment with the selective TGR5 agonist INT-777 was not able to ameliorate the metabolic parameters evaluated. Herein, we report the effects of in vivo OCA dosing on the liver, the VAT, and the adipogenic capacity of VAT preadipocytes (rPADs) isolated from rabbits on a HFD compared with those on a control diet. VAT and liver were studied by immunohistochemistry, Western blot analysis, and RT-PCR. rPADs were exposed to a differentiating mixture to evaluate adipogenesis. Adipocyte size, hypoxia, and the expression of perilipin and cytosolic insulin-regulated glucose transporter GLUT4 (SLC2A4) were significantly increased in VAT isolated from the HFD rabbits, and normalized by OCA. The expression of steatosis and inflammation markers was increased in the liver of the HFD rabbits and normalized by OCA. rPADs isolated from the HFD rabbits were less sensitive to insulin, as demonstrated by the decreased insulin-induced glucose uptake, triglyceride synthesis, and adipogenic capacity, as well as by the impaired fusion of lipid droplets. OCA treatment preserved all the aforementioned metabolic functions. In conclusion, OCA dosing in a MetS rabbit model ameliorates liver and VAT functions. This could reflect the ability of OCA to restore insulin sensitivity in AT unable to finalize its storage function, counteracting MetS-induced metabolic alterations and pathological AT deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 2×
“In addition to insulin resistance and visceral obesity, MetS is accompanied by dyslipidemia with high triglyceride levels and low HDL cholesterol concentrations and hypertension (Després & Lemieux 2006).”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 4×
“In mice fed a high-fat diet (HFD), INT-777, a specific TGR5 agonist without FXR agonist activity (Thomas et al. 2009) lowers serum glucose and insulin levels and improves glucose tolerance (Sato et al. 2007).”
BackgroundInfluentialTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 1×
“During the past few years, bile acids (BAs) have emerged as important modulators of metabolic homeostasis and insulin resistance (Thomas et al. 2008).”
BackgroundBrasaemle, D. L. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700014-jlr200 · Cited by 1,157
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective
Virtue, S., & Vidal-Puig, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.12.006 · Cited by 1,013 · cited 13×
“Indeed, not only the total mass of AT conveys a metabolic risk, but the size http://joe.endocrinology-journals.org 2013 Society for Endocrinology DOI: 10.1530/JOE-13-0109 Printed in Great Britain A CON B HFD C HFD+OCA D E 1 2 3 4 Li pi d dr op le ts v ol um e (µ m 3 ) SNAP23 mRNA F HFD DIM HFD untreated HFD+OCA DIM CO…”
BackgroundResultInfluentialPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 2×
“Structure, potency, and selectivity toward other nuclear hormone receptors have been described previously (Pellicciari et al. 2002, Rizzo et al. 2010).”
BackgroundMethodSelf-citationTimmons, J. A., Wennmalm, K., Larsson, O., Walden, T. B., Lassmann, T., Petrovic, N., Hamilton, D. L., Gimeno, R. E., Wahlestedt, C., Baar, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610615104 · Cited by 732
Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions.
Snel, M., Jonker, J. T., Schoones, J., Lamb, H., de Roos, A., Pijl, H., Smit, J. W. A., Meinders, A. E., & Jazet, I. M. (2012) · International Journal of Endocrinology · doi:10.1155/2012/983814 · Cited by 368 · cited 1×
“This ectopic fat deposition amplifies insulin resistance and can interfere with cellular functions (Després & Lemieux 2006, Virtue & Vidal-Puig 2010, Snel et al. 2012).”
Background
Cited by
Obesity I: Overview and molecular and biochemical mechanisms
Lustig, R. H., Collier, D., Kassotis, C., Roepke, T. A., Kim, M. J., Blanc, E., Barouki, R., Bansal, A., Cave, M. C., Chatterjee, S., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115012 · Cited by 203
Obesity and late-onset hypogonadism
Corona, G., Vignozzi, L., Sforza, A., Mannucci, E., & Maggi, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.031 · Cited by 154
Self-citationMorelli, A., Sarchielli, E., Comeglio, P., Filippi, S., Vignozzi, L., Marini, M., Rastrelli, G., Maneschi, E., Cellai, I., Persani, L., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.017 · Cited by 107
Self-citationNonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
The pathophysiology of abdominal adipose tissue depots in health and disease
Walker, G. E., Marzullo, P., Ricotti, R., Bona, G., & Prodam, F. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0023 · Cited by 90
Metadata
- Authors
- Maneschi, E., Vignozzi, L., Morelli, A., Mello, T., Filippi, S., Cellai, I., Comeglio, P., Sarchielli, E., Calcagno, A., Mazzanti, B., Vettor, R., Vannelli, G. B., Adorini, L., & Maggi, M.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2013-06-07
- Volume
- 218
- Issue
- 2
- Pages
- 215-231
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2075017111
- Cited by
- 68
- References
- 12
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. https://app.cochat.ai/papers/10.1530/joe-13-0109
- The paper
- Maneschi, E., Vignozzi, L., Morelli, A., Mello, T., Filippi, S., Cellai, I., Comeglio, P., Sarchielli, E., Calcagno, A., Mazzanti, B., Vettor, R., Vannelli, G. B., Adorini, L., & Maggi, M. (2013). FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. Journal of Endocrinology. https://doi.org/10.1530/joe-13-0109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.